Hazai Eszter, Bikádi Zsolt
Virtua Drug, Ltd., H-1015 Budapest, Csalogány Street 4, Hungary.
J Struct Biol. 2008 Apr;162(1):63-74. doi: 10.1016/j.jsb.2007.12.001. Epub 2007 Dec 15.
BCRP (also known as ABCG2, MXR, and ABC-P) is a member of the ABC family that transports a wide variety of substrates. BCRP is known to play a key role as a xenobiotic transporter. Since discovering its role in multidrug resistance, considerable efforts have been made in order to gain deeper understanding of BCRP structure and function. The recent study was aimed at predicting BCRP structure by creating a homology model. Based on sequence similarity with known structures of full-length, NB and TM domain of ABC transporters, TM, NB, and linker regions of BCRP were defined. The NB domain of BCRP was modeled using MalK as a template. Based on secondary structure prediction of BCRP and comparison of the transmembrane connecting regions of known structures of ABC transporters, the TM domain arrangement of BCRP was established and was found to resemble to that of the recently published crystal structure of Sav1866. Thus, an initial alignment of TM domain of BCRP was established using Sav1866 as a template. This alignment was subsequently refined using constrains derived from secondary structure and TM predictions and the final model was built. Finally, the complete homodimer ABCG2 model was generated using Sav1866 as template. Furthermore, known ligands of BCRP were docked to our model in order to define possible binding sites. The results of molecular dockings of known BCRP substrates to the BCRP model were in agreement with recently published experimental data indicating multiple binding sites in BCRP.
乳腺癌耐药蛋白(也称为ABCG2、MXR和ABC-P)是ABC家族的成员,可转运多种底物。已知乳腺癌耐药蛋白作为一种外源性物质转运体发挥关键作用。自从发现其在多药耐药中的作用以来,人们为更深入了解乳腺癌耐药蛋白的结构和功能付出了巨大努力。最近的这项研究旨在通过创建同源模型来预测乳腺癌耐药蛋白的结构。基于与ABC转运蛋白全长、核苷酸结合结构域(NB)和跨膜结构域(TM)已知结构的序列相似性,确定了乳腺癌耐药蛋白的TM、NB和连接区。以MalK为模板对乳腺癌耐药蛋白的NB结构域进行建模。基于乳腺癌耐药蛋白的二级结构预测以及对ABC转运蛋白已知结构跨膜连接区的比较,确定了乳腺癌耐药蛋白的TM结构域排列,发现其与最近发表的Sav1866晶体结构相似。因此,以Sav1866为模板建立了乳腺癌耐药蛋白TM结构域的初始比对。随后利用二级结构和TM预测得出的约束条件对该比对进行优化,并构建了最终模型。最后,以Sav1866为模板生成了完整的同型二聚体ABCG2模型。此外,将已知的乳腺癌耐药蛋白配体对接至我们的模型,以确定可能的结合位点。已知乳腺癌耐药蛋白底物与乳腺癌耐药蛋白模型的分子对接结果与最近发表的实验数据一致,表明乳腺癌耐药蛋白存在多个结合位点。